Fresenius raises guidance as growth vectors scale and Helios holds firm
Q2 2026 marks a structural step-up: core EPS guidance lifted to 10-15% CER, with biopharma, MedTech and Helios all contributing.
FRE.DE · Earnings Call · 2026-08-05
A structural step-up, not just another beat
Fresenius delivered an "excellent quarter" that goes beyond routine outperformance. CEO Michael Sen opened the call with a clear signal: “Q2 is another clear proof point that future Fresenius is delivering.” — Michael Sen, CEO · 2026-08-05 The company raised full-year core EPS growth guidance from 5-10% to 10-15% at constant currency, a bold move that reflects broad-based momentum and a higher-quality earnings profile. CFO Sara Hennicken quantified the operating leverage: “EBIT margin expanded by 60 basis points year-on-year to an excellent 12.3%.” — Sara Hennicken, CFO · 2026-08-05
The narrative is one of structural step in the business model—a shift from a fragmented healthcare conglomerate to a focused platform with three growth engines: biopharma, MedTech, and care provision. As Michael put it, "Fresenius is stronger, more focused and better positioned than it was at the start of our transformation." The growth vectors are now material contributors, with biopharma organic revenue up 38% in the quarter and MedTech up 11%.
Kabi: biopharma and MedTech deliver repeatable success
At Kabi, the story is about scaling innovation-led growth. The company announced new in-licensing deals and a key regulatory milestone: “we achieved another important milestone with the U.S. and EU regulatory submission acceptance of vedolizumab, a biosimilar candidate for moderate to severe Ulcerative Colitis or Crohn's disease.” — Michael Sen, CEO · 2026-08-05 The biopharma platform is gaining traction across molecules—Tyenne now holds 44% market share in EU5 and 30% in the U.S., while Bomyntra has reached 11% in the EU5. The Rituximab approval further expands the U.S. portfolio, although Michael acknowledged it is a later entrant in a "more crowded space."
MedTech also delivered a standout quarter, with Ivenix installations at leading hospitals like Mayo Clinic and SSM Health. The installed base is a precursor to recurring revenue from consumables and software—a key point of differentiation. “This is not the Fresenius of a couple of years ago, which is largely predicated to generics in the U.S.” — Michael Sen, CEO · 2026-08-05 The company is now a diversified healthcare player with a stronger pipeline and a more visible earnings trajectory.
Helios: resilience amid regulatory change
Helios delivered a 10.6% EBIT margin, firmly within the structural target range, despite the expiration of the temporary surcharge and ongoing regulatory uncertainty. Michael provided clarity on the German GVSG Stabilization Act, saying it provides "a constructive framework for continued reimbursement growth." The company remains committed to its 10-12% structural margin ambition for Helios, with growth expected from both Germany and Spain. This contrasts with earlier quarters when the company was more guarded about the 2027 headwinds—a point well received by analysts.
Financial strength and strategic flexibility
Cash generation was a highlight, with operating cash flow of €344 million in Q2 and a last-twelve-month cash conversion rate of 1.2x. Leverage remained stable at 2.6x net debt-to-EBITDA, despite the dividend payment. Sara noted that the successful €1 billion bond issuance in July reinforces access to capital and provides "strategic flexibility to invest in profitable growth." The company's balance sheet is a source of confidence, with optionality from the Fresenius Medical Care stake.
Conclusion
Fresenius has turned a corner. The guidance upgrade is not just a quarterly beat but a reflection of a structurally higher earnings base. The OAI status at Melrose Park is a manageable operational issue, and the company's network should mitigate any impact. As Michael said earlier in the year, "We had a very strong finish in Q4, and we are very confident going into 2026 and beyond with everything we have in place." That confidence is now backed by results, and the market is taking notice.